Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Current role of acid suppressants in Helicobacter pylori eradication therapy
Autore:
Labenz, J;
Indirizzi:
Jung Stilling Hosp, Dept Med & Gastroenterol, D-57074 Siegen, Germany JungStilling Hosp Siegen Germany D-57074 terol, D-57074 Siegen, Germany
Titolo Testata:
BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
fascicolo: 3, volume: 15, anno: 2001,
pagine: 413 - 431
SICI:
1521-6918(200106)15:3<413:CROASI>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROTON PUMP INHIBITOR; GASTROESOPHAGEAL REFLUX DISEASE; DOUBLE-BLIND TRIAL; TRIPLE THERAPY; DUODENAL-ULCER; DUAL THERAPY; GASTRIC-MUCOSA; INTRAGASTRIC DISTRIBUTION; ANTIMICROBIAL AGENTS; CAMPYLOBACTER-PYLORI;
Keywords:
amoxicillin; clarithromycin; gastric acidity; Helicobacter pylori; nitroimidazole; proton pump inhibitors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
92
Recensione:
Indirizzi per estratti:
Indirizzo: Labenz, J Jung Stilling Hosp, Dept Med & Gastroenterol, Wichernstr 40, D-57074 Siegen, Germany Jung Stilling Hosp Wichernstr 40 Siegen Germany D-57074 Germany
Citazione:
J. Labenz, "Current role of acid suppressants in Helicobacter pylori eradication therapy", BEST PR RES, 15(3), 2001, pp. 413-431

Abstract

Helicobocter pylori induces chronic active gastritis that may progress to atrophy. Serious clinical consequences are peptic ulcer disease and gastricmalignancies. Today, treatment of the infection is an appropriate option and is strongly recommended in various clinical situations. Although many antibiotics are effective against H. pylori in vitro, few substances are suitable for use in vivo. This is because H, pylori lives in a unique environment in which several factors may affect the pharmacokinetic and pharmacodynamic properties of the anti-microbial agents. One of the most important factors is gastric acidity. This article reviews the effects of acid suppression on H. pylori and the associated gastritis, the potential mechanisms by which antisecretory drugs such as proton pump inhibitors might enhance the activity of anti-microbials in vivo, and the results of clinical trials supporting the current view that proton pump inhibitors are a mainstay in the treatment of this infection.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 12:30:05